Literature DB >> 34100279

Be aware of SARS-CoV-2 spike protein: There is more than meets the eye.

T C Theoharides1,2,3, P Conti4.   

Abstract

The COVID-19 pandemic necessitated the rapid production of vaccines aimed at the production of neutralizing antibodies against the COVID-19 spike protein required for the corona virus binding to target cells. The best well-known vaccines have utilized either mRNA or an adenovirus vector to direct human cells to produce the spike protein against which the body produces mostly neutralizing antibodies. However, recent reports have raised some skepticism as to the biologic actions of the spike protein and the types of antibodies produced. One paper reported that certain antibodies in the blood of infected patients appear to change the shape of the spike protein so as to make it more likely to bind to cells, while other papers showed that the spike protein by itself (without being part of the corona virus) can damage endothelial cells and disrupt the blood-brain barrier. These findings may be even more relevant to the pathogenesis of long-COVID syndrome that may affect as many as 50% of those infected with SARS-CoV-2. In COVID-19, a response to oxidative stress is required by increasing anti-oxidant enzymes. In this regard, it is known that polyphenols are natural anti-oxidants with multiple health effects. Hence, there are even more reasons to intervene with the use of anti-oxidant compounds, such as luteolin, in addition to available vaccines and anti-inflammatory drugs to prevent the harmful actions of the spike protein. Copyright 2021 Biolife Sas. www.biolifesas.org.

Entities:  

Keywords:  ACE2; antibodies; blood vessels; blood-brain barrier; coronavirus; endothelial cells; receptor; spike protein

Mesh:

Substances:

Year:  2021        PMID: 34100279     DOI: 10.23812/THEO_EDIT_3_21

Source DB:  PubMed          Journal:  J Biol Regul Homeost Agents        ISSN: 0393-974X            Impact factor:   1.711


  5 in total

Review 1.  Modified mRNA-Based Vaccines Against Coronavirus Disease 2019.

Authors:  Aline Yen Ling Wang
Journal:  Cell Transplant       Date:  2022 Jan-Dec       Impact factor: 4.139

2.  Long COVID syndrome-associated brain fog.

Authors:  Ali A Asadi-Pooya; Ali Akbari; Amir Emami; Mehrzad Lotfi; Mahtab Rostamihosseinkhani; Hamid Nemati; Zohreh Barzegar; Maryam Kabiri; Zahra Zeraatpisheh; Mohsen Farjoud-Kouhanjani; Anahita Jafari; Sarvin Sasannia; Shayan Ashrafi; Masoume Nazeri; Sara Nasiri; Mina Shahisavandi
Journal:  J Med Virol       Date:  2021-10-24       Impact factor: 20.693

3.  Case Series of Three Neurological Side Effects in Younger-Aged Individuals After Pfizer's mRNA Vaccine.

Authors:  Elliot Dinetz
Journal:  Cureus       Date:  2022-04-03

4.  The effect of an mRNA vaccine against COVID-19 on endothelial function and arterial stiffness.

Authors:  Dimitrios Terentes-Printzios; Vasiliki Gardikioti; Eirini Solomou; Eleni Emmanouil; Ioanna Gourgouli; Panagiotis Xydis; Georgia Christopoulou; Christos Georgakopoulos; Ioanna Dima; Antigoni Miliou; George Lazaros; Maria Pirounaki; Konstantinos Tsioufis; Charalambos Vlachopoulos
Journal:  Hypertens Res       Date:  2022-03-10       Impact factor: 5.528

Review 5.  Therapeutic Strategies for COVID-19 Lung Disease in Children.

Authors:  Elisabetta Gatti; Marta Piotto; Mara Lelii; Mariacarola Pensabene; Barbara Madini; Lucia Cerrato; Vittoria Hassan; Stefano Aliberti; Samantha Bosis; Paola Marchisio; Maria Francesca Patria
Journal:  Front Pediatr       Date:  2022-03-07       Impact factor: 3.418

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.